Ono Pharmaceutical Co., Ltd. (OPHLF)

19.36 0.00 (0.00%) At close: 12:21PM EDT

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Chuo-ku
Osaka 541-8564
Japan
81 6 6263 5670
https://www.ono-pharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 3,761

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gyo Sagara	CEO, Pres & Representative Director	927.08k	N/A	1958
Mr. Masaki Ito	Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax	N/A	N/A	N/A
Takehiro Yamada	Corp. Officer & Sr. Director of Compliance Management Department	N/A	N/A	N/A
Masayuki Tanigawa	Corp. Officer & Exec. Director of Corp. Devel. & Strategy, International Bus.	N/A	N/A	N/A
Mr. Toichi Takino Ph.D.	Sr. Managing Exec. Officer, Head of Research Division & Director	N/A	N/A	1968
Mr. Toshihiro Tsujinaka	Sr. EO, Exec. Director of Sustainability Promotion Corp. Strategy & Planning and Director	N/A	N/A	1964
Hiromu Habashita Ph.D.	Corp. Officer, Dep. Exec. Dir. of Discovery & Research and Research Center of Immunology	N/A	N/A	N/A
Kiyoaki Idemitsu	Managing Exec. Officer, GM of Devel. Division & Director	N/A	N/A	1964
Shinji Takai M.D., Ph.D.	Corp. Officer & Head of Medical Affairs	N/A	N/A	N/A
Satoshi Takahagi	Corp. Officer and Exec. Director of Sales, Marketing & Primary Care Bus. Division	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Corporate governance

Ono Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 September 2023 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.